Company Profile
Galera Therapeutics Stock Price, News & Catalysts
- Ticker:
- GRTX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
17.60 USD (-2.22%)
Close
Last updated: July 10, 2026
—
Market cap
Why the stock is moving
Current closing-price context is not available for GRTX.
Company overview
Business overview
Galera Therapeutics was a biotech company focused on oncology supportive care and radiation-related therapies before its restructuring and decline. Its legacy was centered on protecting patients during cancer treatment.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ before restructuring, Galera sat in specialty oncology biotechnology.
Business Model Characteristics
The business depended on clinical development, regulatory steps, and the challenge of translating supportive-care science into a durable franchise.
Position Within the Biotechnology Landscape
Galera belongs to the historical oncology-biotech group rather than the current live public-company set.
Future catalysts
- Galera is now largely a legacy and closeout story, so the catalysts are corporate resolution rather than a fresh pipeline readout. The market is focused on what value remains after the prior oncology effort.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Galera Therapeutics (GRTX)?
Galera Therapeutics (GRTX) most recently closed at 17.60 USD, a -2.22% move versus the previous session.
What does Galera Therapeutics do?
Galera Therapeutics was a biotech company focused on oncology supportive care and radiation-related therapies before its restructuring and decline. Its legacy was centered on protecting patients during cancer treatment.
On which exchange is GRTX stock listed?
Galera Therapeutics (GRTX) is associated with NASDAQ, United States, Biopharma.
What is Galera?
Galera is now largely a legacy and closeout story, so the catalysts are corporate resolution rather than a fresh pipeline readout.
Which conditions is Galera Therapeutics targeting with Galera?
Galera Therapeutics is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Galera Therapeutics describe recent progress with Galera?
Galera is now largely a legacy and closeout story, so the catalysts are corporate resolution rather than a fresh pipeline readout.
What is Therapeutics?
Galera Therapeutics was a biotech company focused on oncology supportive care and radiation-related therapies before its restructuring and decline.
What should investors watch for with Therapeutics?
Galera is now largely a legacy and closeout story, so the catalysts are corporate resolution rather than a fresh pipeline readout. The market is focused on what value remains after the prior oncology effort.